NCT02893917 2026-03-18
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
48 trialsNCT02345265 2026-03-05
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04090567 2026-03-05
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01391962 2026-02-02
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT02498613 2025-09-25
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02974621 2025-08-03
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00942877 2025-03-03
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04487587 2025-02-26
COMICE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Active not recruiting
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03117933 2024-01-23
OCTOVA
University of Oxford
Phase 2 Completed
NCT02899728 2023-10-17
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01062425 2022-07-26
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02889900 2022-03-08
CONCERTO
AstraZeneca
Phase 2 Completed
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT04184518 2020-06-02
CEDUVEAL-M
Grupo EspaƱol Multidisciplinar de Melanoma
Phase 2 Withdrawn
NCT01132820 2019-08-08
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01337401 2019-01-24
CASPS
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT00436956 2018-10-09
AZD2171 to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00278343 2018-08-29
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00243061 2018-08-27
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00527124 2018-08-09
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01260688 2018-08-08
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00410904 2018-04-13
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00243074 2018-01-23
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00326872 2017-08-18
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01310855 2017-05-31
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
University College, London
Phase 2 Terminated
NCT00588900 2017-04-05
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01229111 2017-03-29
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00326599 2017-03-21
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00475150 2017-02-15
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00423332 2017-02-02
Cediranib (AZD2171, RECENTINā¢) in Metastatic or Recurrent Renal Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00427973 2016-10-31
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00227760 2016-02-29
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00244881 2015-12-07
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
National Cancer Institute (NCI)
Phase 2 Completed
NCT00275028 2015-11-09
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00458978 2015-05-05
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00245063 2014-10-02
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00303862 2014-05-21
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01229930 2013-08-26
Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00305656 2013-08-22
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT01262612 2013-07-15
Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion
Radboud University Medical Center
Phase 2 Terminated
NCT00238394 2013-06-05
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00321724 2013-01-15
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00306891 2012-11-01
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentinā¢)
AstraZeneca
Phase 2 Completed
NCT00278889 2012-10-24
HORIZON I
AstraZeneca
Phase 2 Completed
NCT00385203 2012-07-16
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
AstraZeneca
Phase 2 Completed